360
Views
4
CrossRef citations to date
0
Altmetric
Atopic Dermatitis

Treatment of atopic dermatitis with KAM-3008, a barrier-based, non-steroidal topical cream

&
Pages 426-430 | Received 30 Oct 2014, Accepted 25 Jan 2015, Published online: 20 Apr 2015
 

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with cutaneous hyper-reactivity to environmental triggers, and is characterized by pruritic eczematous skin lesions. Recent insights into the pathophysiology of AD point to the important role that abnormal barrier permeability plays, which leads to compromised hydration, common micro-organismal colonization and immune dysregulation. Current treatment strategies for AD, such as topical corticosteroids and moisturizers, control the disease symptom’s severity and duration. KAM-3008 is a novel, barrier-based, steroid-free, topical cream indicated for the relief of symptoms associated with AD. In addition to moisturizing and emollient ingredients, several herbal extracts have been incorporated into the formulation to enhance its anti-allergic and anti-inflammatory properties. Methods: In this study, the safety and efficacy of KAM-3008 body cream in relieving the symptoms of AD in adult subjects after 7, 14 and 21 days of treatment were investigated using the transepidermal water loss (TEWL), skin hydration and scoring atopic dermatitis (SCORAD) measurements. Results and conclusions: Based on both the quantitative TEWL and qualitative SCORAD assessments, we found that KAM-3008 body cream is a safe, well-tolerated and efficacious stand-alone treatment for the relief of AD symptoms.

Acknowledgements

The authors would like to thank Miri Sani for regulatory and clinical support as well as Yechiel Goldman for valuable editorial assistance.

Declaration of interest

This manuscript describes a company-sponsored study (Kamedis Ltd., Tel Aviv, Israel). Both authors are employed by Kamedis, however neither author was directly involved in the execution of the clinical study described herein.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.